Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China

References

• Lortholary O, Renaudat C, Sitbon K, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive Care Med. 2014;40(9):1303–1312.
   PubMed Web of Science ®Google Scholar
• Sasso M, Roger C, Sasso M, et al. Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: a 10-year study. Mycoses. 2017;60(12):770–780.
   PubMed Web of Science ®Google Scholar
• Goemaere B, Becker P, Van Wijngaerden E, et al. Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. Mycoses. 2018;61(2):127–133.
   PubMed Web of Science ®Google Scholar
• Xiao M, Fan X, Chen SC, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother. 2015;70(3):802–810.
   PubMed Web of Science ®Google Scholar
• Sadeghi G, Ebrahimi-Rad M, Mousavi SF, et al. Emergence of non-Candida albicans species: epidemiology, phylogeny and fluconazole susceptibility profile. J Mycol Med. 2018;28(1):51–58.
   PubMed Web of Science ®Google Scholar
• Khan Z, Ahmad S, Al-Sweih N, et al. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait. PLoS One. 2019;14(5):e216250.
   Web of Science ®Google Scholar
• Da MD, Souza A, Colombo AL. Revisiting species distribution and antifungal susceptibility of Candida bloodstream isolates from Latin American medical centers. J Fungi (Basel). 2017;3(2):24.
   PubMedGoogle Scholar
• Toth R, Nosek J, Mora-Montes HM, et al. Candida parapsilosis: from genes to the bedside. Clin Microbiol Rev. 2019;32(2):e00111-18.
   PubMed Web of Science ®Google Scholar
• Odds FC, Brown AJ, Gow NA. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272–279.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Kim YJ, Yong D, et al. Fluconazole-resistant Candida parapsilosis bloodstream isolates with Y132F mutation in ERG11 gene, South Korea. Emerg Infect Dis. 2018;24(9):1768–1770.
   PubMed Web of Science ®Google Scholar
• Thomaz DY, de Almeida JJ, Lima G, et al. An azole-resistant Candida parapsilosis outbreak: clonal persistence in the intensive care unit of a Brazilian teaching hospital. Front Microbiol. 2018;9:2997.
   PubMed Web of Science ®Google Scholar
• Arastehfar A, Daneshnia F, Hilmioglu-Polat S, et al. First report of candidemia clonal outbreak caused by emerging fluconazole-resistant Candida parapsilosis isolates harboring Y132F and/or Y132F+K143R in Turkey. Antimicrob Agents Chemother. 2020;64(10):e01001-20.
   PubMed Web of Science ®Google Scholar
• Fekkar A, Blaize M, Bougle A, et al. Hospital outbreak of fluconazole-resistant candida parapsilosis: arguments for clonal transmission and long-term persistence. Antimicrob Agents Chemother. 2021;65(5):e02036–20.
   Web of Science ®Google Scholar
• Martini C, Torelli R, de Groot T, et al. Prevalence and clonal distribution of azole-resistant Candida parapsilosis isolates causing bloodstream infections in a large Italian hospital. Front Cell Infect Microbiol. 2020;10:232.
   PubMed Web of Science ®Google Scholar
• Perlin DS. Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci. 2015;1354(1):1–11.
   PubMedGoogle Scholar
• Perlin DS. Current perspectives on echinocandin class drugs. Future Microbiol. 2011;6(4):441–457.
   PubMed Web of Science ®Google Scholar
• Chiotos K, Vendetti N, Zaoutis TE, et al. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12). J Antimicrob Chemother. 2016;71(12):3536–3539.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz M, Aguado JM, Almirante B, et al. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis. 2014;58(10):1413–1421.
   PubMed Web of Science ®Google Scholar
• Arastehfar A, Daneshnia F, Hilmioglu-Polat S, et al. Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge? J Antimicrob Chemother. 2021;76(2):418–422.
   PubMed Web of Science ®Google Scholar
• Davari A, Haghani I, Hassanmoghadam F, et al. Echinocandin resistance in Candida parapsilosis sensu stricto: role of alterations in CHS3, FKS1 and Rho gene expression. J Glob Antimicrob Resist. 2020;22:685–688.
   PubMed Web of Science ®Google Scholar
• Rybak JM, Dickens CM, Parker JE, et al. Loss of C-5 sterol desaturase activity results in increased resistance to azole and echinocandin antifungals in a clinical isolate of Candida parapsilosis. Antimicrob Agents Chemother. 2021;61(9):e00651-17.
   Google Scholar
• Marti-Carrizosa M, Sanchez-Reus F, March F, et al. Implication of Candida parapsilosis FKS1 and FKS2 mutations in reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2015;59(6):3570–3573.
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Katiyar SK, Park S, et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008;52(7):2305–2312.
   PubMed Web of Science ®Google Scholar
• Siopi M, Papadopoulos A, Spiliopoulou A, et al. Pan-echinocandin resistant C. parapsilosis harboring an F652S Fks1 alteration in a patient with prolonged echinocandin therapy. J Fungi. 2022;8(9):931.
   Web of Science ®Google Scholar
• Yi Q, Xiao M, Fan X, et al. Evaluation of Autof MS 1000 and Vitek MS MALDI-TOF MS system in identification of closely-related yeasts causing invasive fungal diseases. Front Cell Infect Microbiol. 2021;11:628828.
   PubMed Web of Science ®Google Scholar
• Reference method for broth dilution antifungal susceptibility testing of yeasts; Fourth Informational Supplement.
   Google Scholar
• Performance standards for antifungal susceptibility testing of yeasts: M27M44S. 2022.
   Google Scholar
• Epidemiological cutoff values for antifungal susceptibility testing: M57S. 2022.
   Google Scholar
• Cantón E, Pemán J, Hervás D, et al. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric sensititre YeastOne method. J Clin Microbiol. 2012;50(12):3921–3926.
   PubMed Web of Science ®Google Scholar
• Gómez-Molero E, Willis JR, Dudakova A, et al. Phenotypic variability in a coinfection with three independent Candida parapsilosis lineages. Front Microbiol. 2020;11:1994.
   PubMed Web of Science ®Google Scholar
• Koboldt DC, Zhang Q, Larson DE, et al. Varscan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568–576.
   PubMed Web of Science ®Google Scholar
• Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools. Gigascience. 2021;10(2):giab008.
   PubMed Web of Science ®Google Scholar
• Cingolani P, Platts A, Wang LL, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6(2):80–92.
   PubMed Web of Science ®Google Scholar
• Hallgren J, Tsirigos K, Pedersen MD, et al. DeepTMHMM predicts alpha and beta transmembrane proteins using deep neural networks. bioRxiv. 2022. 04.08.487609; doi: https://doi.org/10.1101/2022.04.08.487609
   Google Scholar
• Yazar M, Ozbek P. In silico tools and approaches for the prediction of functional and structural effects of single-nucleotide polymorphisms on proteins: an expert review. OMICS. 2021;25(1):23–37.
   PubMed Web of Science ®Google Scholar
• Yang J, Yan R, Roy A, et al. The I-TASSER suite: protein structure and function prediction. Nat Methods. 2015;12(1):7–8.
   PubMed Web of Science ®Google Scholar
• Lombardi L, Oliveira-Pacheco J, Butler G. Plasmid-based CRISPR-Cas9 gene editing in multiple Candida species. Msphere. 2019;4(2):e00125-19.
   PubMed Web of Science ®Google Scholar
• Ke W, Xie Y, Hu Y, et al. A forkhead transcription factor contributes to the regulatory differences of pathogenicity in closely related fungal pathogens. mLife. 2022;1(1):79–91.
   Google Scholar
• Walker LA, Munro CA, de Bruijn I, et al. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 2008;4(4):e1000040.
   PubMed Web of Science ®Google Scholar
• Walker LA, Gow NA, Munro CA. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother. 2013;57(1):146–154.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997-2016. Open Forum Infect Dis. 2019;6(Suppl. 1):S79–S94.
   PubMedGoogle Scholar
• Sakamoto Y, Kawabe K, Suzuki T, et al. Species distribution of candidemia and their susceptibility in a single Japanese university hospital: prior micafungin use affects the appearance of Candida parapsilosis and elevation of micafungin MICs in non-parapsilosis Candida species. J Fungi (Basel). 2021;7(8):596.
   PubMedGoogle Scholar
• Pfaller MA, Messer SA, Woosley LN, et al. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51(8):2571–2581.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46(1):150–156.
   PubMed Web of Science ®Google Scholar
• Khan Z, Ahmad S, Joseph L, et al. Comparative in vitro susceptibility of clinical isolates of andida paparsilosis complex and other Candida species to caspofungin and anidulafungin by Etest. J Chemother. 2011;23(2):97–101.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Jones RN, et al. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). J Antibiot (Tokyo). 2015;68(9):556–561.
   PubMed Web of Science ®Google Scholar
• Xiao M, Chen SC, Kong F, et al. Distribution and antifungal susceptibility of Candida species causing candidemia in China: an update from the CHIF-NET study. J Infect Dis. 2020;221(Suppl. 2):S139–S147.
   PubMedGoogle Scholar
• Patil A, Majumdar S. Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol. 2017;69(12):1635–1660.
   PubMed Web of Science ®Google Scholar
• Moudgal V, Little T, Boikov D, et al. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother. 2005;49(2):767–769.
   PubMed Web of Science ®Google Scholar
• Papp C, Kocsis K, Toth R, et al. Echinocandin-Induced microevolution of Candida parapsilosis influences virulence and abiotic stress tolerance. Msphere. 2018;3(6):e00547–18.
   PubMed Web of Science ®Google Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86(8):805–817.
   PubMed Web of Science ®Google Scholar
• Puerta-Alcalde P, Garcia-Vidal C. Changing epidemiology of invasive fungal disease in allogeneic hematopoietic stem cell transplantation. J Fungi (Basel). 2021;7(10):868.
   PubMedGoogle Scholar
• Cornely OA, Hoenigl M, Lass-Florl C, et al. Defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses. 2019;62(9):716–729.
   PubMed Web of Science ®Google Scholar
• Rolling T, Zhai B, Gjonbalaj M, et al. Haematopoietic cell transplantation outcomes are linked to intestinal mycobiota dynamics and an expansion of Candida parapsilosis complex species. Nat Microbiol. 2021;6(12):1505–1515.
   PubMed Web of Science ®Google Scholar
• Weems JJ, Chamberland ME, Ward J, et al. Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol. 1987;25(6):1029–1032.
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Lee S, Park S, et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009;53(9):3690–3699.
   PubMed Web of Science ®Google Scholar
• Zhou X, Sumrow L, Tashiro K, et al. Mutations linked to neurological disease enhance self-association of low-complexity protein sequences. Science. 2022;377(6601):n5582.
   Web of Science ®Google Scholar